Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Sanofi
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Roswell Park Cancer Institute
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Amgen
University of Michigan Rogel Cancer Center
M.D. Anderson Cancer Center
Thomas Jefferson University
Memorial Sloan Kettering Cancer Center
Therapeutic Advances in Childhood Leukemia Consortium
Fred Hutchinson Cancer Center
Hoffmann-La Roche
Baptist Health South Florida
Ensoma
Celgene
Kyowa Kirin Co., Ltd.
Amgen
Therapeutic Advances in Childhood Leukemia Consortium
Daiichi Sankyo
Stanford University
Bellicum Pharmaceuticals
University of Nebraska
Eastern Cooperative Oncology Group
Rutgers, The State University of New Jersey
University of Pennsylvania
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Fred Hutchinson Cancer Center
Kiadis Pharma
Wake Forest University Health Sciences
Brown University
OHSU Knight Cancer Institute
Therapeutic Advances in Childhood Leukemia Consortium
Spectrum Pharmaceuticals, Inc
Kiadis Pharma
ADC Therapeutics S.A.
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
Therapeutic Advances in Childhood Leukemia Consortium
Masonic Cancer Center, University of Minnesota
Therapeutic Advances in Childhood Leukemia Consortium
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
University of California, San Diego
Juno Therapeutics, a Subsidiary of Celgene
Medical College of Wisconsin